PHIO

Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.

Wall Street analysts forecast PHIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHIO is 14.00 USD with a low forecast of 14.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Phio Pharmaceuticals Corp revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Phio Pharmaceuticals Corp. EPS for the last quarter amounts to -0.44 USD, decreased -71.43 % YoY.

Phio Pharmaceuticals Corp (PHIO) has 5 emplpoyees as of January 10 2026.

Today PHIO has the market capitalization of 12.49M USD.